---
title: "Amycretin"
canonical_url: https://peptidelibrary.app/library/amycretin
description: "Novo Nordisk unimolecular GLP-1 and amylin receptor agonist in oral and subcutaneous forms, advancing to Phase 3. Not FDA-approved. Distinct from CagriSema."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Amycretin

Amycretin (also called Zenagamtide or NN9487) is an investigational GLP-1 + amylin unimolecular agonist. Amycretin is a single molecule that activates both the GLP-1 and amylin receptors, an approach sometimes described as unimolecular co-agonism — combining in one peptide the two satiety pathways that CagriSema addresses with two separate agents.

Novo Nordisk unimolecular GLP-1 and amylin receptor agonist in oral and subcutaneous forms, advancing to Phase 3. Not FDA-approved. Distinct from CagriSema.

Also known as: Zenagamtide, NN9487, Unimolecular GLP-1/amylin agonist.

Categories: Fat Loss, GLP-1/Metabolic.

## Classification

- Type: Investigational GLP-1 + amylin unimolecular agonist
- Mechanism class: GLP-1 Agonist
- Development stage: In clinical development
- Regulatory class: Investigational, not FDA-approved

## Mechanism

Amycretin is a single molecule that activates both the GLP-1 and amylin receptors, an approach sometimes described as unimolecular co-agonism — combining in one peptide the two satiety pathways that CagriSema addresses with two separate agents. GLP-1 receptor activation contributes glucose-dependent insulin secretion, slowed gastric emptying and central appetite suppression, while amylin receptor activation acts principally through hindbrain nuclei to reduce meal size. Both subcutaneous and oral formulations have been studied in early-phase trials. It is investigational and not approved for any use.

Targets: GLP-1 receptor, Amylin receptor.

Origin: Synthetic unimolecular dual agonist (Novo Nordisk).

## Properties

- Studied routes: Subcutaneous, Oral

## Evidence

- Evidence level: Clinical Trial Evidence
- Highest documented: Controlled human trials
- Human trials: 4
- Controlled human trials: 4
- Preclinical sources: 0
- Latest source: 2026

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: phase 2 trial. Lancet. 2026. 2026. Controlled human trial. Population: Adults with type 2 diabetes on metformin with or without an SGLT2 inhibitor (n=262) [Source](https://pubmed.ncbi.nlm.nih.gov/42532080/)
2. Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: phase 2 trial. Lancet. 2026. 2026. Controlled human trial. Population: Adults with type 2 diabetes on metformin with or without an SGLT2 inhibitor (n=186) [Source](https://pubmed.ncbi.nlm.nih.gov/42532079/)
3. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. Lancet. 2025. 2025. Controlled human trial. Population: Adults aged 18–55 with overweight or obesity (n=125) [Source](https://pubmed.ncbi.nlm.nih.gov/40550231/)
4. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1 trial. Lancet. 2025. 2025. Controlled human trial. Population: Adults aged 18–55 with overweight or obesity (n=144). Mild or moderate adverse events, mostly gastrointestinal, more frequent at higher doses; exposure was dose-proportional [Source](https://pubmed.ncbi.nlm.nih.gov/40550229/)

## Safety

Side effects: GI class effects.

Risks: Not approved; WADA S0.

Human safety basis: Clinical trial reports

Key limitations: Not approved by the FDA for any use..

## Regulatory status

Amycretin has been studied under an Investigational New Drug application. It is not approved for marketing.

- FDA status: Investigational New Drug (IND)
- WADA status: Banned in Sport
- Availability: Research-Only

## Frequently asked questions

### What is Amycretin?

Novo Nordisk unimolecular GLP-1 and amylin receptor agonist in oral and subcutaneous forms, advancing to Phase 3. Not FDA-approved. Distinct from CagriSema.

### How does Amycretin work?

Amycretin is a single molecule that activates both the GLP-1 and amylin receptors, an approach sometimes described as unimolecular co-agonism — combining in one peptide the two satiety pathways that CagriSema addresses with two separate agents. GLP-1 receptor activation contributes glucose-dependent insulin secretion, slowed gastric emptying and central appetite suppression, while amylin receptor activation acts principally through hindbrain nuclei to reduce meal size.

### Is Amycretin FDA approved?

No. Amycretin is investigational: it is in clinical development and has not been approved by the FDA for any indication. Investigational status means trials are ongoing or complete but regulatory review has not resulted in approval, and efficacy and safety are still being established.

### Is Amycretin banned in sport?

Amycretin is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.

### What peptides are similar to Amycretin?

Compounds most often compared with Amycretin include Cagrilintide, Pramlintide, Petrelintide and CagriSema. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial — Lancet, 2026](https://pubmed.ncbi.nlm.nih.gov/42532080/)
- [Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial — Lancet, 2026](https://pubmed.ncbi.nlm.nih.gov/42532079/)
- [Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study — Lancet, 2025](https://pubmed.ncbi.nlm.nih.gov/40550231/)
- [Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial — Lancet, 2025](https://pubmed.ncbi.nlm.nih.gov/40550229/)
- [Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives — Metabolism, 2026](https://pubmed.ncbi.nlm.nih.gov/41850421/)

Note: Dose figures are left out of this Markdown version. See the cited sources.
